A business.com editor verified this analysis to ensure it meets our standards for accuracy, expertise and integrity. Business.com earns commissions from some listed providers. Editorial Guidelines.

Poster 11: Literature Review: Acetylcholinesterase Inhibitors and Effects on Mortality in Alzheimer's Disease and Related Dementias Poster 12: Literature Review: Acetylcholinesterase Inhibitors and ...

Kyverna is currently conducting multiple clinical trials with KYV-101, including registrational trials for stiff person syndrome and myasthenia gravis, as well as Phase 1/2 trials for lupus nephritis.

Already a subscriber? Click the image to view the latest e-edition. Don't have a subscription? Click here to see our subscription options. The Courier Express mobile app brings you the latest local ...

BAAR, Switzerland - Novocure (NASDAQ:NVCR), a $1.47 billion medical technology company whose shares have declined over 55% year-to-date, will present research data on its Tumor Treating Fields ...

A business.com editor verified this analysis to ensure it meets our standards for accuracy, expertise and integrity. Business.com earns commissions from some listed providers. Editorial Guidelines.

The Central Board of Secondary Education (CBSE) has issued a fourth reminder to all affiliated schools regarding the submission of registration data for Class IX and Class XI for the academic year ...

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve ...

ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation LONDON and PHILADELPHIA, Oct. 13, ...